A Study of SHR-A1909 in Subjects With Advanced Malignant Tumors

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; * Patients must have cytologically or histologically confirmed advanced malignant tumor, and must have failed standard treatment; * Toxicities caused by prior anti-tumor treatments must have resolved to CTCAE Grade ≤ 1 prior to the first dose (except for alopecia or hypothyroidism treated with hormone replacement therapy or diabetes controlled with insulin); * Adequate organ function. Exclusion Criteria: * With CNS infiltration, or ascites requiring paracentesis or symptomatic pleural effusion; * Received prior CAR T-cell therapy; * Received allogeneic hematopoietic stem cell transplantation within 3 months prior to the start of study treatment, or with acute/chronic graft versus host disease; * With active infection or fever of unknown origin (\> 38.5 °C).